3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
4
Thoracic
2
Head & Neck
2
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Hepatocellular
10
Colorectal Neoplasms
9
Rectal Neoplasms
8
Pancreatic Neoplasms
8
Wilms Tumor
7
Neuroblastoma
7
Lymphoma, Non-Hodgkin
7
Hepatoblastoma
7
Glioma
7
Sarcoma
6
Rhabdomyosarcoma
6
Rhabdoid Tumor
6
Osteosarcoma
6
Neuroectodermal Tumors, Primitive, Peripheral
6
Medulloblastoma
6
Histiocytosis, Langerhans-Cell
6
Ependymoma
6
Lung Neoplasms
5
Central Nervous System Neoplasms
5
Stomach Neoplasms
4
Sarcoma, Ewing
4
Ovarian Neoplasms
4
Esophageal Neoplasms
4
Colonic Neoplasms
4
Melanoma
3
Endometrial Neoplasms
3
Uterine Cervical Neoplasms
2
Prostatic Neoplasms
2
Lymphoma
2
Liver Neoplasms
2
Interventions
pembrolizumab
39
Nivolumab
15
Gemcitabine
8
spartalizumab
7
atezolizumab
7
Carboplatin
7
Cyclophosphamide
6
130-nm albumin-bound paclitaxel
6
durvalumab
5
Cisplatin
5
Bevacizumab
5
fludarabine
4
budigalimab
4
Paclitaxel
4
Oxaliplatin
4
Leucovorin
4
Ipilimumab
4
Fluorouracil
4
Cetuximab
4
Albumin-Bound Paclitaxel
4
tislelizumab
3
lenvatinib
3
cemiplimab
3
avelumab
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Irinotecan
3
HMPL-013
3
Fulvestrant
3
Docetaxel
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
X-Rays
×
Gastrointestinal
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled